A Pilot Study of Bone Mineral Density in Postmenopausal Women After Treatment for Breast Cancer

Inclusion Criteria: * Documented diagnosis of breast cancer * Last menstrual period occurring more than 5 years ago * Non-metastatic breast cancer tumor with the diagnosis of Tis, Tl-T4, N0-3, M0 * DCIS is allowed, but LCIS (only) is not Exclusion Criteria: * Any metabolic bone disease other than postmenopausal osteoporosis or osteopenia * Use of systemic gonadal hormonal medications or supplements within the past 24 months * Prior use of tamoxifen or raloxifene is permitted if the medication was discontinued more than 24 months prior to the diagnosis of breast cancer. * No adjuvant antiestrogen, antineoplastic, therapies are permitted on study. * Chronic use of systemic steroids for disease process other than breast cancer chemotherapy premedication or antiemetics * History of rheumatoid arthritis, ankylosing spondylitis, hyperparathyroidism, renal osteodystrophy, moderate to severe inflammatory or autoimmune disease or newly diagnosed thyroid condition requiring titration of medications. * Lobular carcinoma in situ or Stage IV breast cancer and patients with a concurrently active second malignancy other then adequately treated non-melanoma skin cancers or in situ cervical cancer. * participation in other clinical trials that are measuring BMD as a study parameter * Patients with conditions that are expected to distort BMD reading and make DEXA results unreliable * Patients with concurrent medical or psychiatric conditions that would keep them from understanding and complying with this clinical trial.